NuMedii has landed a deal that could validate its data-driven approach to drug discovery. Allergan is the company to give a shot to NuMedii, signing up to source a flow of potential treatments for psoriasis from the Stanford University spinout.
Eisai has become the latest in a long line of companies to look to IT outsourcing for cost savings. The drugmaker has handed responsibility for the maintenance, operation and monitoring of much of its IT infrastructure in Japan and the U.S. to Accenture in a pair of long-term deals. Accenture is contracted to do the work in Japan until 2024 and in the U.S. until 2022. Only a portion of Eisai's R&D network is excluded from the 7-year U.S. deal, while the agreement in Japan goes beyond servers and other IT infrastructure to cover some of its accounting, production management and other enterprise resource planning systems. The idea is to increase efficiencies through the establishment of a global governance structure and drive down IT costs, prospects that have been luring drugmakers to strike outsourcing deals for years. Read more >>
POPULAR COMMENT THREADS
Illumina has detailed how it intends to start generating income from its cloud app platform BaseSpace. The plan includes the creation of two paid-for packages that bundle together assorted features, some of which are targeted specifically at larger organizations.
WuXi NextCODE has added another country to its growing list of large-scale sequencing projects. Sidra Medical and Research Center, which is involved with the Qatar Genome Project, has turned to WuXi NextCODE for help.
UBiome has become the first for-profit organization to roll out an app for Apple ResearchKit, the tech giant's open-source study platform. The program is combining a ResearchKit-enabled app with uBiome's microbiome test to generate data that may one day support biopharma R&D.
When Gilead's Sovaldi and AbbVie's Viekira Pak came to market, physicians had little real-world evidence for either drug on which to base their prescribing decisions. In an attempt to fill this gap and find out what happens to hepatitis C patients between physician visits, Boston Children's Hospital has created an app for Apple ResearchKit.
GlaxoSmithKline has provided a glimpse at just how much information about the real-world use of drugs is online. In a trawl of Facebook and Twitter, the Big Pharma found 21 million mentions of its products--and the data have already led to the recall of a GSK product.
The University of California, San Francisco (UCSF) has snagged $9.75 million to build a platform for the remote collection of research data. UCSF will use the cash to build out its mobile data gathering toolkit, giving it the capabilities to support large-scale, geographically-dispersed research programs.
From Our Sister Sites
Moderna Therapeutics' top scientist has quietly left the much-discussed company after two years at the helm of its R&D operation, walking away from a cash-flush biotech with big ambitions.
A new company spun out of Harvard University's Wyss Institute raised $5.15 million in Series A cash to develop a technology its founders say can generate images of unprecedented resolution, creating a new avenue for diagnostics and drug discovery.